Camp4 Therapeutics Corp

Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical enterprise focused on discovering and developing regulatory RNA-targeting therapeutics. The organization utilizes its proprietary RAP Platform and antisense oligonucleotides to upregulate gene expression and restore protein levels across central nervous system disorders and other genetic indications. Its lead product candidate is CMP-002, an investigational treatment designed to address SYNGAP1-related developmental and epileptic encephalopathy. Additionally, the company is researching treatments for other encephalopathy indications and metabolic conditions, including urea cycle disorders via candidate CMP-001. Camp4 targets patient populations affected by rare and prevalent haploinsufficient conditions, while partnering with large pharmaceutical organizations such as GlaxoSmithKline to co-develop treatments.

The company operates without internal manufacturing facilities, relying on third-party contract organizations to package, label, store, distribute, and manufacture its investigational medicines. Its clinical trial evaluations and commercial partnerships encompass international activities, including clinical trial authorization in the Netherlands and regulatory filings in the United States. The excerpt does not disclose the location of the corporate headquarters.

Summary of the business section of Camp4 Therapeutics's latest annual report, written by StockData.

“As of December 31, 2025, we had 48 employees, all of whom were full-time and 34 of whom were engaged in research and development activities.”